Therapeutic area data reported by biopharma companies on phase I trials in March 2020, including: Actinium, Allergan, Aptevo, Aravive, Arrowhead, Artugen, Asana, Biocryst, Biomx, Bolt, Cabaletta, CNS, Cohbar, Compugen, Cyclo, Cytodyn, Dare, Debiopharm, Decibel, Discgenics, Dynacure, Enlivex, Eton, Evelo, Faron, Fulcrum, Gemoab, Genetx, Gilead Sciences, GT, Imcheck, Immutep, Inflarx, Inflazome, Inmed, Innate, Kancera, Kiniksa, Lattice, Matinas, Medivir, Mersana, Mina, Moderna, Novartis, Oncolytics, Oncopeptides, Oncternal, Orchard, Pliant, Prevail, Psioxus, Redhill, Seelos, Synlogic, Targovax, Terns, Tolero, Uniqure.